Sort
48,018 grants matching “immunotherapy”
Mechanisms of T Cell Quiescence and Exhaustion
$645,962Surojit Sarkar · Seattle Children'S Hospital · R01 · FY2025 · AI
Mechanisms of T Cell Quiescence and Exhaustion
$645,958Surojit Sarkar · Seattle Children'S Hospital · R01 · FY2024 · AI
Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma
$645,873Wen Jiang · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma
$645,873Wen Jiang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies
$645,746James Even Voss · Scripps Research Institute, The · R01 · FY2022 · AI
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
$645,738Emese Zsiros · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA
Designer extracellular vesicles for cancer therapy
$645,726Xiaowei Xu · University Of Pennsylvania · R01 · FY2025 · CA
Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer
$645,632Stacey Deleria Finley · University Of Southern California · U01 · FY2021 · CA
Understanding hematopoietic stem cell dysfunction in refractory Crohn's disease
$645,617Louis Jared Cohen · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · DK
Develop lung-targeted synthetic lipid nanoparticles for mRNA medicine treating pulmonary lymphangioleiomyomatosis
$645,566Qiaobing Xu · Tufts University Medford · R01 · FY2025 · HL
Variation in tumor-associated immune profiles and colorectal cancer outcomes
$645,534Stephanie L. Schmit · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · CA
Generation of tumor specific immunity in canine osteosarcoma through dendritic cell hyperactivation
$645,473Cheryl A London · Tufts University Boston · U01 · FY2022 · CA
Decoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.
$645,401Nagireddy Putluri · Baylor College Of Medicine · R01 · FY2023 · CA
Evaluation of the Immunogenicity of a Stabilized MD39 Env Glycoprotein Trimer when Delivered through a Novel Alum Slow Release Technology with or without Other Adjuvants
$645,369Pyone Aye · Tulane University Of Louisiana · N01 · FY2019 · AI
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy
$645,363Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA
Mechanism of acid signaling in bone organ metastases on tumor and myeloid cell evolution towards immune suppression and tumor progression
$645,323Katherine Nelson Weilbaecher · Washington University · R01 · FY2025 · CA
Leveraging canine spontaneous cancer to optimize the power of blood biopsy
$645,307Elinor Karlsson · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · CA
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies
$645,211David R Boulware · University Of Minnesota · R01 · FY2025 · AI
Immunoregulatory role of lung-resident club cell factors in lung cancer
$645,197Vivek Mittal · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy
$645,019Ze Lu · Optimum Therapeutics, Llc · R44 · FY2009 · CA
Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer
$644,986Robert H Vonderheide · University Of Pennsylvania · R01 · FY2022 · CA
Predictive Markers in Metastatic Renal Cancer
$644,954Frederic M. Waldman · University Of California, San Francisco · R01 · FY2009 · CA
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes
$644,903Kevan C Herold · Yale University · R01 · FY2024 · DK
Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapy
$644,840Alireza Faridar · Methodist Hospital Research Institute · R01 · FY2025 · AG
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials
$644,838Eric C Holland · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA